Fig. 6
From: Group testing performance evaluation for SARS-CoV-2 massive scale screening and testing
Expansion rates of single-pass and two-pass schemes at different prevalences. The expansion rates, showing how many folds the testing capacity can be expanded to include presumably negative dominant scan population (e.g. extending the tracing to not only symptomatic but also to asymptomatic contacts) conducting the same number of tests